By the conclusion of this video,
you will be able to describe how to view toxicity within the context
of a molecule's indication. You will also be able to demonstrate how
to quantify the safety of a molecule. As we think about measuring
toxicity of a molecule, we often must define which adverse events
are most relevant to a patient and how much risk are patients
willing to accept. The table on the screen shows
some factors to consider. Let's assume that we have a molecule
with an adverse effect maybe a frequent incidence of headaches. Now, let's look at the table
with proposed uses. If our molecule prevents osteoporosis and
is taken over a long period, then from a patient perspective,
a high probability of headaches will likely be a key
barrier to taking the drug. Keep in mind that frequency or likelihood
of the adverse effect is also important. If both were very low,
say developing a headache was unlikely or might only occur every few months,
a patient with osteoporosis might very well accept the relatively minor risk
to obtain the benefit from the drug. If on the other hand,
our molecule can potentially treat cancer, a patient will likely
overlook the headache risk. In fact, cancer patients often accept
drugs with significantly higher risks and more severe side effects due to
the severity of the disease and limited treatment options. On the screen is a set of curves
that show response curves for both the desired therapeutic effect, pharmacodynamics that's in green,
and a toxic effect that's in red. Note the relationship between the PD and toxicity curves will be different for
every drug. Exposure is quantified on the x-axis. Exposure can be quantified
in different ways, such as the peak concentration
of a drug C MAX or the area under the curve, AUC. At an exposure that is just high enough to generate a pharmacological response, the toxicity is nearly 0. Just causing a response with no
therapeutic benefit, however, is not satisfactory for a drug. A higher exposure will be required for a therapeutic effect, and a higher exposure may also
lead to a higher risk or incidence of toxicity. Furthermore, because patient responses to
a particular dose of a drug are variable, drugs are normally dosed above
a minimally efficacious level to achieve the desired therapeutic
response or registration endpoint. Again, as the intended exposure increases,
the incidence of toxicity also rises. The difference between
the required exposure for a particular amount of
therapeutic benefit and the exposure that triggers
unacceptable toxicity allows quantification of safety parameters for
a molecule. Two such measures are therapeutic
index and safety margin. These measures are not identical, but both attempt to convey the balance of
risks and benefits for a molecule. We will discuss them in more
depth in another video. By specifically defining
the types of toxicity relevant to a particular molecule and program,
we can generate quantitative measures to weigh the risks and
benefits for a molecule.